News
Bayer faces Swiss criminal probe over cerivastatin
BMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7330.130b (Published 19 January 2002) Cite this as: BMJ 2002;324:130- Fiona Fleck
- Geneva
Prosecutors in the Swiss canton of Ticino have opened a criminal inquiry into Bayer AG on suspicion of fraud and grievous bodily damage following the German pharmaceutical giant's controversial recall of its cholesterol drug cerivastatin sodium in August last year.
Cantonal prosecutor Nicola Respini told the BMJ on Friday that he had opened the investigation on 4 December after a patient taking cerivastatin (marketed as Lipobay …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.